Clinical Trials Logo

Clinical Trial Details — Status: Suspended

Administrative data

NCT number NCT03071653
Other study ID # 001001001
Secondary ID
Status Suspended
Phase Phase 2
First received
Last updated
Start date November 24, 2016
Est. completion date February 2022

Study information

Verified date May 2021
Source University of Cape Town
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A randomized controlled trial to test the potential safety and efficacy of LCSD in patients with heart failure due to non-ischemic and ischemic cardiomyopathy at the University of Cape Town. Left Cardiac Sympathetic Denervation (LCSD) is a surgical intervention that modulates the autonomic innervation of the cardiac system. This is important because: a] sympathetic and parasympathetic tone has a profound effect on the threshold for ventricular tachyarrhythmias-the main cause of sudden cardiac death in this population; and b] autonomic dysfunction (which is characterized by an imbalance between sympathetic and parasympathetic activation), plays an important detrimental role in the pathophysiology and progression of heart failure.


Description:

STUDY SUMMARY TITLE Left Cardiac Sympathetic Denervation (LCSD) for Cardiomyopathy Study DESIGN Phase II feasibility parallel randomised controlled trial (RCT) AIMS Assess the feasibility and safety of LCSD in patients with cardiomyopathy and heart failure OUTCOME MEASURES Recruitment rates, retention, follow-up and safety POPULATION 30 patients with heart failure secondary to cardiomyopathy ELIGIBILITY Adult participants with ischemic and non-ischemic cardiomyopathy DURATION 18 months follow up METHODS: Participants will be randomized to receive LCSD in addition to optimal medical therapy in the intervention arm (15 patients) and optimal medical therapy in the active control arm (15 patients). Participants would be recruited from both inpatient and outpatient general medical and cardiology wards and clinics at Groote Schuur Hospital where patients with the syndrome of heart failure are frequently referred for subspecialty evaluation and management. Eligible patients who meet the inclusion criteria would be randomized to undergo LCSD in addition to optimal medical therapy (intervention arm) or receive standard optimal medical therapy (active placebo). Optimal therapy for patients with cardiomyopathy and heart failure currently consists of an ace-inhibitor or angiotensinogen receptor blocker, beta-blocker, mineralocorticoid receptor antagonist with or without a loop diuretic, and digoxin. All patients in the study would receive an implantable loop recorder to allow for the accurate determination of episodes of symptomatic and asymptomatic ventricular tachyarrhythmias. In order not to lose all of the clinical outcome information obtained in the pilot phase of the study, we would propose only assessing the pre-specified feasibility and safety aspects of the study and keeping the data on efficacy outcomes blinded for inclusion in the fully powered main study. The LCSD procedure The procedure involves the surgical removal of the lower half of the left stellate ganglion (T1) and thoracic ganglia (T2-T4), thereby removing the pro-arrhythmic noradrenergic input to the ventricles (3). LCSD raises the ventricular fibrillation threshold without impairing cardiac contractility or reducing heart rate. LCSD results in pre-ganglionic denervation, thus preventing re-innervation and producing permanent antifibrillatory effects. This procedure can be performed by video-assisted thoracoscopic surgery (VATS) usually in less than 45 minutes and will be conducted by thoracic surgeons at Groote Schuur Hospital. The lead thoracic surgeon (J.R.) has a large experience in performing this procedure for the indication of hyperhidrosis in over 200 patients (personal communication). This experienced thoracic surgeon will lead a team of thoracic surgeons (T.P., L.M.) to perform the procedure. Implantable loop recorder (ILR) insertion The implantable loop recorder is a small device that will be inserted at the end of the LCSD procedure by the thoracic surgeon or after enrolment in the optimal medical therapy arm by a cardiologist. This loop recorder is inserted under sterile conditions in the catheter laboratory or operating theatre. In the catheter laboratory, the device is inserted under local anaesthetic, subcutaneously over the left precordium and usually takes less than 15 minutes. The implantable loop recorder is a well-established device to quantify and detect atrial and ventricular tachyarrhythmias with an excellent safety record. The device has a battery life of up to 3 years and can be removed via a small skin incision at the end of the study. Implantable loop recorder insertion does not carry risk of known major complications. There is a minimal risk (<1%) of complications (infection, bleeding) as the device is implanted subcutaneously. Potential complications include superficial skin infections that readily responds to antibiotics. Device removal is easy to perform and is seldom required. Optimal Medical Therapy All eligible patients with heart failure and depressed left ventricular systolic function will receive guideline and evidence based optimal tolerated medical therapy. The level of risk associated with optimal medical therapy is considered very low. For the majority of patients with heart failure and depressed left ventricular systolic function this will include: 1. A renin angiotensin system blocker at highest tolerated doses (e.g., enalapril 10mg twice daily or equivalent) 2. A mineralocorticoid receptor antagonist (e.g., Spironolactone 25-50mg daily or equivalent) 3. A Beta-blocker (e.g., Carvedilol 25mg twice daily or equivalent) 4. The use of a loop diuretic and digitalis will be clinically driven and used at the discretion of the attending clinician


Recruitment information / eligibility

Status Suspended
Enrollment 30
Est. completion date February 2022
Est. primary completion date November 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - At least 18 years of age - New York Heart Association (NYHA) II/III stable heart failure due to an ischemic or non-ischemic cardiomyopathy with a Left Ventricular Ejection Fraction <=35% based on Echocardiogram, ERNA or MRI performed in the last 12 months. For the purpose of this study, Ischemic cardiomyopathy will be defined as Left Ventricular systolic dysfunction (Ejection Fraction <35%) associated with 75% narrowing of at least 1 of the 3 major coronary arteries, a documented history of a ST elevation myocardial infarction or significant regional wall motion abnormality on an echocardiogram. Non-ischemic cardiomyopathy will be defined as Left Ventricular systolic dysfunction <35% in the absence of known coronary artery disease or regional wall motion abnormality on echocardiography. - No history of a prior cardiac arrest or sustained (>30 seconds or <30s if haemodynamically unstable) ventricular tachyarrhythmia. - Signed informed consent forms will be available in IsiXhosa, Afrikaans and English. Exclusion Criteria: - History of prior unexplained syncope, sudden cardiac arrest or ventricular arrhythmia - Peripartum cardiomyopathy or cardiomyopathy associated with thyrotoxicosis - History of coronary revascularization or percutaneous intervention in the preceding 3 months - Myocardial infarction in the preceding 1 month - NYHA IV at enrollment - Patient taking an antiarrhythmic drug (not including beta-blockers) - Pregnancy - Any non-cardiac condition that is associated with a high likelihood of death during the trial such as major organ dysfunction or malignancy.

Study Design


Intervention

Procedure:
Left Cardiac Sympathetic Denervation (LCSD)
The procedure involves the surgical removal of the lower half of the left stellate ganglion (T1) and thoracic ganglia (T2-T4), thereby removing the pro-arrhythmic noradrenergic input to the ventricles
Other:
Optimal Medical Therapy
All eligible patients with heart failure and depressed left ventricular systolic function will receive guideline and evidence based optimal tolerated medical therapy. The level of risk associated with optimal medical therapy is considered very low. For the majority of patients with heart failure and depressed left ventricular systolic function this will include: A renin angiotensin system blocker at highest tolerated doses (e.g., enalapril 10mg twice daily or equivalent) A mineralocorticoid receptor antagonist (e.g., Spironolactone 25-50mg daily or equivalent) A Beta-blocker (e.g., Carvedilol 25mg twice daily or equivalent) The use of a loop diuretic and digitalis will be clinically driven and used at the discretion of the attending clinician

Locations

Country Name City State
South Africa University of Cape Town Cape Town Western Cape

Sponsors (2)

Lead Sponsor Collaborator
University of Cape Town Medtronic

Country where clinical trial is conducted

South Africa, 

Outcome

Type Measure Description Time frame Safety issue
Primary Feasibility of recruiting Recruitment rate 36 months
Primary Feasibility of performing the procedure in recruited patients Patient retention 36 months
Primary Procedure related complications Measured by:• Horner's syndrome in those under going LCSD • Pneumothorax in those undergoing LCSD • Implantable loop recorder site sepsis 36 months
Secondary Mortality and morbidity Measured by: All cause mortality; Heart failure related mortality; Hospital admissions; Ventricular arrhythmias; 36 months
Secondary Functional capacity: Measured by 6 minute walk test Quality of life at 6 months Admission to hospital for heart failure Functional Capacity Measured by 6 minute walk test 6 monthly for 36 months
Secondary Functional capacity: Quality of life (EQ-5D questionnaire) Quality of life at 6 months Admission to hospital for heart failure Functional Capacity Quality of life (EQ-5D questionnaire) 6 monthly for 36 months
Secondary End Systolic and Diastolic volumes End Systolic and Diastolic volumes as determined by Echocardiography 6 monthly for 36 months
See also
  Status Clinical Trial Phase
Recruiting NCT05564689 - Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy
Recruiting NCT04982081 - Treating Congestive HF With hiPSC-CMs Through Endocardial Injection Phase 1
Not yet recruiting NCT04703751 - Evaluation of the CIRCULATE Catheter for Transcoronary Administration of Pharmacologic and Cell-based Agents N/A
Recruiting NCT01157299 - Hemodynamic Evaluation of Preload Responsiveness in Children by Using PiCCO N/A
Completed NCT00765518 - Use of Ixmyelocel-T (Formerly Cardiac Repair Cell [CRC] Treatment) in Patients With Heart Failure Due to Dilated Cardiomyopathy (IMPACT-DCM) Phase 2
Completed NCT02115581 - Coenzyme Q10 Supplementation in Children With Idiopathic Dilated Cardiomyopathy Phase 4
Recruiting NCT04246450 - Arrhythmic Risk Stratification in Nonischemic Dilated Cardiomyopathy N/A
Recruiting NCT05799833 - Low QRS Voltages in Young Healthy Individuals and Athletes
Recruiting NCT01914081 - Resveratrol: A Potential Anti- Remodeling Agent in Heart Failure, From Bench to Bedside Phase 3
Recruiting NCT02915718 - A Clinical Study of Immunoadsorption Therapy for Dilated Cardiomyopathy N/A
Recruiting NCT03061994 - Metabolomic Study of All-age Cardiomyopathy N/A
Completed NCT03893760 - Assessment of Right Ventricular Function in Advanced Heart Failure
Not yet recruiting NCT01219452 - Intramuscular Injection of Mesenchymal Stem Cell for Treatment of Children With Idiopathic Dilated Cardiomyopathy Phase 1/Phase 2
Recruiting NCT02175836 - Arrhythmia Prediction Trial N/A
Active, not recruiting NCT00962364 - Long-term Evaluation of Patients Receiving Bone Marrow-derived Cell Administration for Heart Disease
Recruiting NCT05026112 - The Arrhythmogenic Potential of Midwall Septal Fibrosis in Dilated Cardiomyopathy
Recruiting NCT05237323 - Micophenolate Mofetil Versus Azathioprine in Myocarditis Phase 3
Recruiting NCT04649034 - Intraventricular Stasis In Cardiovascular Disease
Completed NCT02619825 - Non-Invasive Evaluation of Myocardial Stiffness by Elastography in Pediatric Cardiology (Elasto-Pédiatrie) N/A
Recruiting NCT02989181 - Continues Positive Airway Pressure Treatment for Patients With Dilated Cardiomyopathy and Obstructive Sleep Apnea Phase 3